Tilray’s Q3 earnings show promising signs of improving fundamentals with expanding margins and effective cost management, combined with a clean balance sheet. Management’s strategy shift to ...

TILRAY ($TLRY) posted quarterly earnings results on Tuesday, April 8th. The company reported earnings of -$0.10 per share, missing estimates of -$0.04 by $0.06. The ...

Tilray entered penny stock territory quite some time ago, but throughout April, it was literally worth pennies. It traded ...

Tilray Brands, Inc. (NASDAQ:TLRY) Q3 2025 Earnings Call Transcript April 8, 2025 Tilray Brands, Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.04.

Analysts expect Eton Pharmaceuticals to report an earnings per share (EPS) of $0.03. The announcement from Eton ...

Tilray Brands missed Q3 expectations but improved its balance sheet, with net debt at $14 million. Read why I maintain my strong buy rating on TLRY stock.

Despite short-term challenges, Tilray’s focus on margin improvement and strategic market expansion helped the company post earnings that beat expectations, despite missing revenue targets.

A total of 5 analyst ratings have been received for Zevra Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $22.0, suggesting a potential 179.54% upside.

Tilray Brands (NasdaqGS:TLRY) launched a new beverage line, "Cruisies," focusing on ready-to-drink cocktails. This product-related announcement coincided with a period when Tilray's shares rose 10%, ...

Tilray Inc (NASDAQ:TLRY – Free Report) – Alliance Global Partners reduced their FY2025 earnings estimates for shares of Tilray in a research report issued to clients and investors on Wednesday ...

Adjusted earnings are expected to come in at $1.61 ... beating analysts’ expectations by 1.9%, and Tilray reported a revenue decline of 1.4%, falling short of estimates by 10.1%.